Morgan Stanley Vaccinex, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.44 - $131.17 $28 - $8,394	-64 Reduced 17.58%	300 $0
Q3 2022 Nov 14, 2022	BUY	$0.48 - $109.22 $30 - $6,990	64 Added 21.33%	364 $0
Q2 2022 Oct 27, 2022	SELL	$1.05 - $1.39 $903 - $1,195	-860 Reduced 74.14%	300 $0
Q2 2022 Aug 15, 2022	SELL	$1.05 - $1.39 $903 - $1,195	-860 Reduced 74.14%	300 $0
Q1 2022 Oct 27, 2022	BUY	$0.92 - $1.94 $791 - $1,668	860 Added 286.67%	1,160 $1,000
Q1 2022 May 13, 2022	BUY	$0.92 - $1.94 $791 - $1,668	860 Added 286.67%	1,160 $1,000
Q4 2021 Feb 14, 2022	SELL	$1.04 - $2.12 $209 - $426	-201 Reduced 40.12%	300 $0
Q3 2021 Nov 15, 2021	BUY	$2.11 - $2.81 $1,057 - $1,407	501 New	501 $1,000

426K

Ticker VCNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,664,100
Market Cap $46.5M
Description
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab,...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.